Epinomics teams up with Parker’s I-O Institute for biomarker work

Epinomics will work with billionaire Sean Parker's cancer center

Researchers from Epinomics have penned a collaboration with the Parker Institute for Cancer Immunotherapy to use biomarkers from the company to help boost outcomes and lower adverse events in immunotherapy trials.

The deal sees Epinomics work with the Institute’s director Crystal Mackall. The center was set up with funds from the Facebook and Napster billionaire Sean Parker, who is also funding what could be the first CRISPR trials in the U.S.

“The insights from this work will serve to direct further improvements for these therapeutics that will be pursued at Stanford and the set of biomarkers will be employed in clinical use moving forward,” said Fergus Chan, who co-founded Epinomics back in 2013.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“Joining forces with Dr. Mackall and her team at Stanford will enable us to bring precision medicine to these immunotherapies.”

Dr. Mackall added: “I know we will benefit greatly from the expertise Epinomics has in the epigenomics field, including their analytics platform that is advancing therapeutic development efforts and discovery of biomarkers for use in clinical care for immuno-oncology applications.”

Paul Giresi, also a co-founder of Epinomics, says that immunotherapy has proved in some patients to be a strong new class of cancer medicine, helping the immune system to attack tumors.

But he explained that, to date, there is no ‘gold standard’ when it comes to either application or monitoring for this type of therapy, and it is not always clear which patients will benefit from these new types of drug.  

“The key to unlocking this potential in immuno-oncology has been the development of a new technology for reading the epigenome and creation of a deep analytics framework that serves as a central intelligence hub for understanding immune function in human health and disease,” he said.

“Using this framework can derive measures (biomarkers) of immune function across both healthy baseline samples and disease to enable investigators to pinpoint the key immunological features that are the drivers of human disease and are predictive of clinical outcomes.”

Financial terms were not disclosed. 


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.